Cargando…

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression

Although Y‐box binding protein‐1 (YB‐1) is known to be overexpressed in prostate cancer, especially castration‐resistant prostate cancer (CRPC), the mechanism of its overexpression remains unclear. We aimed to elucidate the mechanism of YB‐1 overexpression in CRPC. Gene amplification in CRPC cells a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiota, Masaki, Sekino, Yohei, Tsukahara, Shigehiro, Abe, Tatsuro, Kinoshita, Fumio, Imada, Kenjiro, Ueda, Shohei, Ushijima, Miho, Nagakawa, Shohei, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Uchiumi, Takeshi, Oda, Yoshinao, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780013/ https://www.ncbi.nlm.nih.gov/pubmed/33064355 http://dx.doi.org/10.1111/cas.14695

Ejemplares similares

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
por: Tsukahara, Shigehiro, et al.
Publicado: (2022)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016)

Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor
por: Abe, Tatsuro, et al.
Publicado: (2018)

Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients
por: Igami, Ko, et al.
Publicado: (2022)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

A rare case of PSA-negative metastasized prostate cancer to the stomach with serum CEA and CA19-9 elevation: a case report
por: Shindo, Koji, et al.
Publicado: (2020)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
por: Nishimura, Kazuo, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity
por: Matsumoto, Takashi, et al.
Publicado: (2017)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade
por: Tanaka, Kentaro, et al.
Publicado: (2018)

The Expression of Ubiquitous Mitochondrial Creatine Kinase Is Downregulated as Prostate Cancer Progression
por: Amamoto, Rie, et al.
Publicado: (2016)

Investigation of neutron-deficient isotopes $^{160}$Yb, $^{161}$Yb, $^{163}$Yb and $^{165}$Yb
por: Adam, J, et al.
Publicado: (1976)

Papillary renal cell carcinoma with massive hematoma mimicking hemangioma
por: Hiraki, Yoshiki, et al.
Publicado: (2019)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer
por: Takakura, Michiko, et al.
Publicado: (2012)

Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Distributive Nd-to-Yb Energy Transfer within Pure [YbNdYb] Heterometallic Molecules
por: Maniaki, Diamantoula, et al.
Publicado: (2023)

Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction
por: Kiyokoba, Ryo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rqkg5r52ef1h5i2b7il96iu8b6